Analysts expect that Innophos Holdings, Inc. (NASDAQ:IPHS) will report earnings per share (EPS) of $0.51 for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Innophos’ earnings. Innophos reported earnings per share of $0.52 in the same quarter last year, which would suggest a negative year over year growth rate of 1.9%. The business is scheduled to announce its next quarterly earnings results on Wednesday, February 20th.

On average, analysts expect that Innophos will report full year earnings of $2.25 per share for the current financial year. For the next fiscal year, analysts anticipate that the business will report earnings of $2.50 per share. Zacks’ earnings per share averages are an average based on a survey of analysts that follow Innophos.

Innophos (NASDAQ:IPHS) last issued its earnings results on Thursday, November 1st. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.01). Innophos had a net margin of 2.49% and a return on equity of 13.30%. The company had revenue of $196.93 million during the quarter, compared to analyst estimates of $197.20 million. During the same quarter in the previous year, the company posted $0.78 EPS. The company’s quarterly revenue was up 7.1% on a year-over-year basis.

Several brokerages have recently issued reports on IPHS. BidaskClub cut shares of Innophos from a “buy” rating to a “hold” rating in a report on Wednesday, July 25th. Zacks Investment Research cut shares of Innophos from a “hold” rating to a “strong sell” rating in a report on Thursday, October 25th. ValuEngine cut shares of Innophos from a “hold” rating to a “sell” rating in a report on Friday, October 12th. Finally, TheStreet cut shares of Innophos from a “b-” rating to a “c+” rating in a report on Thursday, August 23rd.

Shares of Innophos stock traded down $0.92 during trading hours on Friday, hitting $29.86. The company had a trading volume of 110,528 shares, compared to its average volume of 211,253. Innophos has a twelve month low of $27.46 and a twelve month high of $50.40. The company has a current ratio of 2.79, a quick ratio of 1.36 and a debt-to-equity ratio of 1.01. The stock has a market cap of $611.84 million, a price-to-earnings ratio of 12.14 and a beta of 1.21.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 6.43%. The ex-dividend date of this dividend is Thursday, November 15th. Innophos’s dividend payout ratio is currently 78.05%.

Large investors have recently modified their holdings of the stock. Itau Unibanco Holding S.A. acquired a new stake in Innophos during the 2nd quarter worth $144,000. Raymond James & Associates acquired a new stake in Innophos during the 2nd quarter worth $209,000. Ifrah Financial Services Inc. acquired a new stake in Innophos during the 2nd quarter worth $210,000. Dynamic Technology Lab Private Ltd acquired a new stake in Innophos during the 2nd quarter worth $217,000. Finally, Alps Advisors Inc. acquired a new stake in Innophos during the 2nd quarter worth $213,000. Hedge funds and other institutional investors own 94.76% of the company’s stock.

Innophos Company Profile

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.